MDK and ovarian carcinoma: The data obtained in this study confirm that the measurement of plasma concentrations of MDK and AGR2 individually display utility as biomarkers for ovarian cancer and that when included in a multi-analyte panel may significantly improve the diagnostic utility of CA125 in symptomatic women.